Seaweed-derived Rhamnan Sulfate and Vascular Function

Last updated: May 8, 2023
Sponsor: University of Texas at Austin
Overall Status: Active - Recruiting

Phase

N/A

Condition

Vascular Diseases

Treatment

Rhamnan sulfate

Clinical Study ID

NCT05651230
STUDY00003693
  • Ages 35-85
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The primary aim of the proposed investigation is to examine the hypothesis that a relatively short period of rhamnan sulfate supplementation would improve key markers of vascular dysfunction in middle-aged and older adults with at least one risk factors for cardiovascular disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • at least one risk factor for cardiovascular disease (e.g., dyslipidemia, hypertension,obesity, impaired fasting glucose)
  • a BMI of <40 kg/m2

Exclusion

Exclusion Criteria:

  • gastrointestinal disorders and/or renal disease
  • pregnancy or lactation
  • strenuous physical activity (>3 times/week)
  • alcohol abuse

Study Design

Total Participants: 15
Treatment Group(s): 1
Primary Treatment: Rhamnan sulfate
Phase:
Study Start date:
April 01, 2023
Estimated Completion Date:
May 01, 2024

Connect with a study center

  • Cardiovascular Aging Research Lab at UT Austin

    Austin, Texas 78712
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.